BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 02 2024 - 7:00AM
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that
the compensation committee of BioCryst’s board of directors granted
five newly-hired employees stock options to purchase an aggregate
of 46,850 shares, and restricted stock units (RSUs) covering an
aggregate of 19,435 shares, of BioCryst common stock. The options
and RSUs were granted as of June 28, 2024, as inducements material
to each employee entering into employment with BioCryst. The
options and RSUs were granted in accordance with Nasdaq Listing
Rule 5635(c)(4).
The options have an exercise price of $6.18 per
share, which is equal to the closing price of BioCryst common stock
on the grant date. The options and RSUs vest in four equal annual
installments beginning on the one-year anniversary of the grant
date, in each case subject to the new employee’s continued service
with the company. Each stock option has a 10-year term. The options
and RSUs are subject to the terms and conditions of BioCryst’s
Inducement Equity Incentive Plan and a stock option agreement or
restricted stock unit agreement, as applicable, covering the
grant.
About BioCryst
PharmaceuticalsBioCryst Pharmaceuticals is a global
biotechnology company with a deep commitment to improving the lives
of people living with complement-mediated and other rare diseases.
BioCryst leverages its expertise in structure-guided drug design to
develop first-in-class or best-in-class oral small-molecule and
protein therapeutics to target difficult-to-treat diseases.
BioCryst has commercialized ORLADEYO® (berotralstat), the first
oral, once-daily plasma kallikrein inhibitor, and is advancing a
pipeline of small-molecule and protein therapies. For more
information, please visit www.biocryst.com or follow us on
LinkedIn.
BCRXW
Contact:John Bluth+1 919 859
7910jbluth@biocryst.com
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Jul 2024 to Aug 2024
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Aug 2023 to Aug 2024